With nearly two decades of experience in the animal health industry, Kissel has been an integral part of Boehringer Ingelheim’s (BI) success. He began his career with BI in sales and marketing and has led teams in Germany, Austria, Southeast Asia and China. In 2002 he was named Global Head of Business Development and charged with growing the animal health business through mergers and acquisitions, including the most recent acquisition of certain assets of Fort Dodge Animal Health.
“Dr. Kissel has always demonstrated excellent leadership qualities,” says George Heidgerken, Kissel’s predecessor, who recently was named Head of Corporate Division Animal Health. “He will continue to grow our business and tenaciously seek opportunities to bring value to our customers.”
Most recently as vice president, Americas, Kissel created and implemented business strategies for Canada, the United States, Mexico, Australia, New Zealand, Southern Africa and all countries in South America.
“Dr. Kissel has a vast amount of experience in the animal health industry, which will only aid in his ability to lead BIVI in coming years,” says Heidgerken.
Kissel, a native of Germany, will be relocating to the St. Joseph, Mo. area with his family.
“I look forward to the many opportunities that lie ahead,” says Kissel. “We continue to invest in personnel, facilities and technology, while pursuing our mission to improve productivity for livestock producers and the quality of life for companion animals and their owners.”
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit: www.bi-vetmedica.com.